WO2007123790A1 - Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties - Google Patents
Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties Download PDFInfo
- Publication number
- WO2007123790A1 WO2007123790A1 PCT/US2007/008054 US2007008054W WO2007123790A1 WO 2007123790 A1 WO2007123790 A1 WO 2007123790A1 US 2007008054 W US2007008054 W US 2007008054W WO 2007123790 A1 WO2007123790 A1 WO 2007123790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- oil
- active agent
- composition
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention is directed to nanostructured compositions having antibacterial, anti- fungal, anti-yeast, and/or anti-viral properties.
- the compositions are useful as drug delivery carriers for one or more active agents or, in the absence of an active agent, in methods where such compositions are desirable.
- Microbial preservatives are added to nonsterile dosage forms to protect them from microbiological growth or from microorganisms that are introduced inadvertently during or subsequent to the manufacturing process.
- antimicrobial preservatives are added to inhibit the growth of microorganisms that may be introduced by repeatedly withdrawing individual doses.
- an antimicrobial agent to a therapeutic dosage form can be undesirable, as such compounds can be toxic and they can have undesirable interactions with the primary active agent to be delivered.
- the use of microbiocides can promote the generation of drug resistant bacteria, drug resistant yeast, drug resistant fungi, etc. This has been observed with the wide spread use of antibacterial lotions, soaps, cleaning products, etc.
- the USP specifies testing for effectiveness in killing E. coli, P. aeruginosa, and S. aureus, plus acting to control and limit the growth of C. albicans, and A. niger, to determine the antimicrobial effectiveness of a dosage form. See USP 26 Section 51, General Chapters, "Antimicrobial Effectiveness Testing.” These particular microorganisms are representative of the most problematic and troublesome bacteria, fungi, and yeast.
- Aspergillus niger is a fungus and one of the most common species of the genus Aspergillus. It causes black mold on certain types of fruit and vegetables, and is a common contaminant of food.
- C. albicans is the major fungal pathogen of humans. Infections can be localized, such as vaginal infections and oral infections, which cause a considerable degree of discomfort. In some patient groups, whose defense system is severely compromised (prematurely born infants, leukemics and burn patients), the yeast can turn into a deadly pathogen causing systemic infections - up to 50% of the patients infected die as a result. The incidence of such infections is increasing rapidly, especially in hospitalized patients. In New Zealand, such infections are now ten times more frequent than they were 15 years ago. Moreover, the reservoir of an ⁇ -Candida drugs is very limited, and these agents can have severe side effects.
- E. coli is an ubiquitous bacteria, with a large number of known strains.
- the particularly deadly E. coli strain E. coli O157:H7 is a member of the EHEC - enterohemorrhagic E. coli group. Enterohemorrhagic means an intestinally-related organism which causes hemorrhaging - and therefore, loss of blood.
- E. coli O157:H7 produces a toxin, called Shiga-like toxin (SLT) or Vero toxin.
- SLT Shiga-like toxin
- Vero toxin The toxin is a protein which causes severe damage to intestinal epithelial cells. This condition is particularly dangerous to small children, and may be lethal, as children are too small to tolerate significant blood and fluid loss.
- HUS hemolytic uremic syndrome
- Pseudomonas aeruginosa is a Gram-negative bacterium that is noted for its environmental versatility, ability to cause disease in particularly susceptible individuals, and its resistance to antibiotics.
- the most serious complication of cystic fibrosis is respiratory tract infection by the ubiquitous bacterium Pseudomonas aeruginosa. Cancer and burn patients also commonly suffer serious infections by this organism, as do certain other individuals with immune systems deficiencies.
- P. aeruginosa has a remarkable capacity to cause disease in susceptible hosts. It has the ability to adapt to and thrive in many ecological niches, from water and soil to plant and animal tissues.
- the bacterium is capable of utilizing a wide range of organic compounds as food sources, thus giving it an exceptional ability to colonize ecological niches where nutrients are limited.
- P. aeruginosa can produce a number of toxic proteins which not only cause extensive tissue damage, but also interfere with the human immune system's defense mechanisms. These proteins range from potent toxins that enter and kill host cells at or near the site of colonization to degradative enzymes that permanently disrupt the cell membranes and connective tissues in various organs.
- Staphylococcus aureus is a leading cause of soft tissue infections, as well as toxic shock syndrome (TSS) and scalded skin syndrome.
- TSS toxic shock syndrome
- the pathogenic effects of Staph are mainly associated with the toxins it produces. Most of these toxins are produced in the stationary phase of the bacterial growth curve. In fact, it is not uncommon for an infected site to contain no viable Staph cells.
- the S. aureus enterotoxin causes quick onset food poisoning which can lead to cramps and severe vomiting. Infection can be traced to contaminated meats which have not been fully cooked.
- These microbes also secrete leukocidin, a toxin which destroys white blood cells and leads to the formation of pus and acne. Particularly, S.
- aureus has been found to be the causative agent in such ailments as pneumonia, meningitis, boils, arthritis, and osteomyelitis (chronic bone infection). Most S. aureus are penicillin resistant, but vancomycin and nafcillin are known to be effective against most strains.
- the molds such as Aspergillus fumigatus are filamentous fungi. They are especially prevalent growing on the nonliving organic materials in the soil. They disperse their nonsexual spores called conidia in the air. Most Aspergilli are harmless to humans and A. fumigatus in particular is harmless to humans whose immune system has not been compromised by disease, drug therapy or genetic conditions. Exposure to A. fumigatus can cause an allergic response in sensitive individuals. More importantly, A. fumigatus is an opportunistic pathogen of bone marrow transplant patients, AIDS patients, and other immune compromised individuals.
- Aspergillus fumigatus is the most common mold causing infection worldwide. The first infection described in man, an aspergilloma, was reported in Edinburgh in 1842 and many cases of invasive disease in non-immunocompromised patients have been reported. These cases and more recent epidemiological data emphasize that A. fumigatus is a primary, albeit rare, pathogen of man. Allergic disease due to Aspergillus was first described in London in 1952 and the first invasive (and fatal) infection in an immunocompromised patient was described in 1953 in the British Medical Journal in a patient from Gloucester. The frequency of invasive disease has risen approximately 14-fold over the 12 years to 1992, as judged after death in unselected autopsies.
- Invasive aspergillosis has overtaken candidiasis as the most frequent fungal pathogen detected post mortem in tertiary care hospitals in Europe. Thus 4% of all patients dying had invasive aspergillosis, compared with about 2% with invasive candidiasis.
- Patients at risk based on the disease frequency include those with chronic granulomatous disease (25-40%), lung transplant recipients (17-26%), allogeneic bone marrow transplant patients (4-30%), neutropenic patients with leukemia (5- 25%), heart transplant recipients (2-13%), pancreas transplant recipients (1-4%), renal transplant patients in Europe and the USA ( ⁇ 1%) and in India ( ⁇ 10%), and patients with AIDS, multiple myeloma and severe combined immunodeficiency ( ⁇ 4%).
- Acute leukemia affects about 3/100,000 of the population and on average each patient receives 3 cycles of chemotherapy, with each cycle defining a major risk period. Similar incidence is observed for high grade lymphoma patients who are also at high risk of invasive aspergillosis. In the industrialized nations alone these treatment protocols generate about 250,000 periods of major risk per year. AIDS cases are predicted to exceed 40 million by the end of the year 2000 which would result in about 1.4 million cases of invasive aspergillosis, although in developing countries most patients will not live long enough to get this disease. The crude mortality from invasive aspergillosis is around 85% and falls to around
- Aspergillus causes a number of other diseases in man. These include aspergilloma ("colonization" of existing pulmonary cavities), sinusitis in normal people, allergic bronchopulmonary and sinus infections, keratitis (which usually leads to blindness in that eye and is common in the developing world) and postoperative infections in immunocompetent patients. Aspergilloma numbers are set to rise dramatically due to the increasing incidence of tuberculosis and such aspergilloma cases are notoriously difficult to treat.
- Aspergillus flavus is the etiologic agent in a wide range of infections including mycotoxicoses owing to aflotoxins, hypersensitivity pneumonitis, otitis, sinusitis, and invasive disease. Some reports suggest the disease process may be potentiated by aflotoxins, particularly in the immunocompromised/neutropenic host. The organism is extremely angioinvasive with resultant necrosis and infarction.
- Ease of active pharmaceutical agent delivery is a key issue facing pharmaceutical companies that develop and commercialize therapeutic products.
- An active agent that is readily soluble in water, for example, is not difficult to formulate into a suitable dosage form.
- formulating poorly water-soluble active agent into suitable dosage forms poses a significant challenge. This is because the human body is a water based system; thus, as a condition of producing therapeutic activity, a drug must dissolve following administration.
- Some poorly water-soluble active agents are never commercialized because they cannot be effectively solubilized, and therefore fail to exhibit acceptable in vivo therapeutic activity.
- the quantity of poorly water-soluble active agent required to be administered to achieve an acceptable level of therapeutic activity may be too great, given the poor water solubility of the agent, and result in unacceptable toxicity.
- an active agent is formulated into a liquid, wherein the active agent is solubilized in a solvent, such dosage forms sometimes perform sub-optimally. For example, such dosage forms may have unpredictable properties or induce undesirable side effects.
- One prior method for particle size reduction is wet milling. This method requires grinding of an active agent with beads made of hard glass, ceramic, porcelain, zirconium oxide, zirconium silicate, polymeric resin, or other suitable substance in a media in which the active agent is poorly soluble, such as water. The active agent is physically converted into much smaller particles that remain suspended in the grinding media. The resultant micron- or nanometer- sized active agent particles can then be isolated from the grinding media by methods such as filtration or centrifugation, and formulated into an appropriate dosage form. See U.S.
- Patent Nos. 5,145,684; 5,518,187; 5,862,999; and 5,718,388 The media in which the active agent is ground typically contains one or more compounds that function as a surface stabilizer for the active agent.
- the surface stabilizers adsorb to the surface of the active agent and act as a steric barrier to active agent particle size growth.
- wet milling techniques therefore produce a "bi-phasic" system in which the stabilized active agent nanoparticles are suspended in the aqueous media.
- the nanoparticulate drug delivery technology commercialized by Elan Drug Delivery (King of Prussia, PA) under the trade name NanoCrystal ® technology, and SkyePharma, pic's Insoluble Drug Delivery (IDD ® ) technology exemplify such wet milling techniques.
- wet milling of active agent has drawbacks, principally being the cost of the process. The added cost for formulating a poorly water-soluble active agent into a nanoparticulate composition utilizing wet milling can be prohibitive. Additionally, amorphous compounds are not amenable to wet milling techniques.
- Nanoparticulate active agent compositions include precipitation, homogenization, and super critical fluid methods.
- Microprecipitation is a method of preparing stable dispersions of poorly soluble active agents. Such a method comprises dissolving an active agent in a solvent followed by precipitating the active agent out of solution.
- Homogenization is a technique that does not use milling or grinding media.
- Active agent in a liquid media constitutes a process stream propelled into a process zone, which in a Microfluidizer ® (Microfluidics, Inc.) is called the Interaction Chamber.
- the geometry of the interaction chamber produces powerful forces of sheer, impaction, and cavitation which are responsible for particle size reduction.
- 5,510,118 refers to a bi-phasic process using a Microfluidizer ® resulting in nanoparticulate active agent particles.
- supercritical fluid methods of making nanoparticulate active agent compositions comprise dissolving an active agent in a solution. The solution and a supercritical fluid are then co-introduced into a particle formation vessel. The temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid. Examples of known supercritical methods of making nanoparticles include International Patent Application No. WO 97/144407 and U.S. Patent No. 6,406,718.
- the invention is directed to nanostructured compositions having antimicrobial, antifungal, anti-yeast, and/or anti-viral properties.
- the compositions comprise at least one oil, at least one surfactant, at least one solvent, and water. Additionally, the compositions can comprise an active agent.
- the active agent can be useful, for example, as a pharmaceutical, diagnostic, or cosmetic.
- Another aspect of the invention is directed to pharmaceutical compositions comprising a nanostructured composition according to the invention, as well as one or more desired pharmaceutically acceptable carriers and/or desired excipients which may include viscosity modifiers, colors, flavoring agents, fragrances, etc.
- One aspect of the invention is directed to a unique active pharmaceutical ingredient nano-structured formulation, which comprises (1) a micelle component, (2) a hydro-alcoholic component, i.e., a mixture of water and water-miscible solvent, (3) an oil-in- water emulsion droplet component, and optionally (4) a solid particle component of an active agent. Any or all of these components may comprise a desired active pharmaceutical, diagnostic, cosmetic, or other active ingredient.
- the active agent may be in solution, as denoted in components 1 to 3, or it may be in precipitated suspension form, as is the case in component 4.
- the solubilized form when the composition is applied to the skin, the solubilized form travels across the skin and into. deeper dermal layers, such as into the dermis.
- the other components such as the micelles, oil fraction, and/or the particulate drug may typically position themselves towards the Stratum corneum of the skin layer.
- certain compounds may position themselves in different layers of epidermis and dermis, while others might permeate directly across the skin.
- This composite formulation avoids having to incorporate chemical permeation enhancers that are otherwise necessary to induce transdermal permeation of the active pharmaceutical ingredient.
- Another aspect of the invention is directed to a method for preparing the nanostructured compositions of the invention comprising: (a) combining a mixture of at least one oil, at least one solvent, and at least one surfactant (also referred to as a surface stabilizer) to form an emulsion base, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
- a surfactant also referred to as a surface stabilizer
- an exemplary method of making the composition comprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
- Figure 1 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according to the protocol specified in USP 25, ⁇ 51>, pp. 1869- 1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), and A. niger (ATCC 16404)).
- Figure 2 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according the protocol specified in USP 25, ⁇ 51>, pp. 1869-1871, but with additional microorganisms (P. aeruginosa ATCC 13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus).
- Figure 3 shows the results of antibacterial effectiveness testing for estradiol compositions of the invention conducted according to the protocol specified in USP 25, ⁇ 51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), and A. niger (ATCC 16404)).
- Figure 4 shows the results of antibacterial effectiveness testing for testosterone compositions of the invention conducted according to the protocol specified in USP 25, ⁇ 51>, pp. 1869- 1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), and A. niger (ATCC 16404)).
- Figure 5 shows the estradiol particle size in a nanostructured composition following homogenization.
- Figure 6 shows the estradiol particle size in a nanostructured composition following the Silverson Method.
- Figure 7 shows the testosterone particle size in a nanostructured composition following homogenization.
- the invention is directed to nanostructured compositions that surprisingly have antimicrobial, anti-fungal, anti-yeast, and/or anti-viral properties.
- the nanostructured compositions of the invention comprise at least one solvent, at least one oil, at least one surface stabilizer (also referred to as a surfactant), and aqueous medium.
- the compositions additionally may comprise oi ⁇ e or more active agents, which may be dissolved or dispersed in any one of the oil, solvent, or water.
- the active agent can be useful, for example, as a pharmaceutical or cosmetic. No external antibacterial agent or preservative is required to be added to the compositions of the invention to impart the antimicrobial, anti -yeast, anti-fungal, and/or anti -viral properties.
- compositions of the invention meet the Antimicrobial Effectiveness Testing criteria as described in the United States Pharmacopoeia (USP — General Chapters, Section 51). This is demonstrated by the testing described in Example 4 below, in which various microbes were cultured in the presence of a composition according to the invention (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), A. niger (ATCC 16404), P. aeruginosa (ATCC 13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus). The results of the testing are also shown in Figure 1, which graphically shows the dramatic antimicrobial properties of the compositions of the invention.
- the standard USP testing requires evaluation in five microorganisms: Aspergillus niger (ATCC 16404), Candida albicans (ATCC 10231 ), Escherichia coli (ATCC 8739), Pseudomonas aeruginosa (ATCC 9027) and Staphylococcus aureus (ATCC 6538). Additional strains were used to confirm the anti -microbial effectiveness in A. flavus, A. fumigatus, P aeruginosa (ATCC 25619) and P. aeruginosa (ATCC 13388). As shown in Figure 2, which graphically shows the results of this testing, antimicrobial effectiveness in these additional strains confirm beyond doubt that the composition vehicle itself is antimicrobial.
- compositions of the invention comprising estradiol and testosterone also exhibited significant antimicrobial effects, and satisfied the USP testing requirements for demonstrating antimicrobial activity. See also Figures 3 and 4.
- compositions of the invention are particularly useful in products used for topical treatment of infections, wound healing, etc., as in addition to the pharmacologic properties of the active agent in such compositions, the vehicle itself acts as a microbicidal agent.
- a composition possibly induces synergistic action and reduces the possibility of development of drug resistance microorganisms.
- such a composition may enable the use of lower doses of the active agent.
- compositions require the addition of an antimicrobial agent to retard microbial growth.
- an antimicrobial agent to retard microbial growth.
- Choosing the right antimicrobial agent can be challenging due to potential interactions between the active agent and the antimicrobial agent.
- the antimicrobial agent can b.e toxic and it can induce adverse reactions in patients.
- compositions comprise an active agent, and the active agent is selected from the group consisting of, but not limited to fenofibrate, estradiol, alendronic acid, acyclovir, paclitaxel, and cyclosporine.
- the oil is selected from the group consisting of, but not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), and wheat germ oil.
- almond oil sweet
- apricot seed oil borage oil
- canola oil coconut oil
- corn oil cotton seed oil
- fish oil jojoba bean oil
- lard oil linseed oil (boiled)
- Macadamia nut oil medium chain triglycerides
- mineral oil olive oil
- peanut oil safflower oil
- sesame oil sesame oil
- the solvent is selected from the group consisting of, but not limited to isopropyl myristate, triacetin, N-methyl pyrrolidinone, aliphatic and aromatic alcohols, polyethylene glycols, and propylene glycol.
- Other examples of useful solvents are long-chain alcohols.
- Ethyl alcohol and benzyl alcohol are yet other examples of alcohols that may be used in the present invention.
- the stabilizer or surfactant is selected from the group consisting of, but not limited to, sorbitan esters, glycerol esters, polyethylene glycol esters, block polymers, acrylic polymers (such as Pemulen ® ), ethoxylated fatty esters (such as Cremophor ® RH-40), ethoxylated alcohols (such as Brij ® ), ethoxylated fatty acids (such as Tween 20), monoglycerides, silicon based surfactants,, and polysorbates.
- sorbitan esters such as Pemulen ®
- ethoxylated fatty esters such as Cremophor ® RH-40
- ethoxylated alcohols such as Brij ®
- ethoxylated fatty acids such as Tween 20
- the sorbitan ester stabilizer is Span ® or Arlacel ® ; the glycerol ester is glycerin monostearate; the polyethylene glycol ester is polyethylene glycol stearate; the block polymer is a Pluronic ® ; the acrylic polymer is Pemulen ® ; the ethoxylated fatty ester is Cremophor RH-40; the ethoxylated alcohol is Brij ® ; the ethoxylated fatty acid is Tween ® 20, or a combination thereof.
- a homogenizing step is performed via a high-pressure system at 1,000 to 40,000 psi.
- the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 10 microns. In other embodiments of the invention, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less
- the first method does not require the presence of an active agent.
- at least one oil, at least one solvent, and at least one surfactant are combined to form an emulsion base, water is added to the emulsion base, and (c) the mixture is homogenized or vigorously stirred.
- an exemplary method of making the composition comprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
- a non-miscible liquid such as an oil, solvent, and water or buffer to form an emulsion base, followed by homogenization or vigorous stirring of the emulsion base.
- Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High velocity homogenization or vigorous stirring, producing forces of high shear and cavitation, are preferred. High shear processes are preferred as low shear processes can result in larger active agent particle sizes.
- the resultant composition is a composite mixture of active agent suspended in the emulsion droplet (nano-emulsion fraction) and sterically stabilized microcrystalline and/or nanocrystalline active agent in the media.
- This tri-phasic system comprises particulate drug, oil, and water or buffer.
- the resultant micro/nano-particulate active agent has an effective average particle size of less than about 3 microns. Smaller particulate active agent can also be obtained, as described below.
- the active agent can be precipitated out from the oil droplets by adding more of the non-miscible liquid.
- the precipitated active agent typically has an effective average particle size of less than about 3 microns. If desired, the active agent particles can be prevented from aggregating or clumping together by incorporating a surfactant or emulsifier, i.e., a "surface stabilizer.”
- Route II is utilized for an active agent that is soluble in at least one part of the emulsion base, such as the solvent.
- an active agent is dissolved in a mixture of oil, solvent, and stabilizer to form an emulsion pre-mix.
- the active agent remains in soluble form if water or buffer is not added to the mixture.
- the active agent is precipitated into micro/nanoparticles having an effective average particle size of less than about 3 microns. Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High energy input, through high velocity homogenization or vigorous stirring, is a preferred process.
- the high energy processes reduce the size of the emulsion droplets, thereby exposing a large surface area to the surrounding aqueous environment.
- High shear processes are preferred, as low shear processes can result in larger particle sizes.
- This is followed by precipitation of nanoparticulate active agent previously embedded in the emulsion base.
- the end product comprises active agent in solution and particulate suspension, both distributed between the solvent, oil, and water or buffer.
- nanoparticulate active agent has at least one surface stabilizer associated with the surface thereof.
- active agent examples include estradiol, which is soluble in ethanol, and fenof ⁇ brate, which is freely soluble in 1 -methyl-2-pyrrolidone or N-methyl-pyrrolidinone [NMP], slightly soluble in oil and stabilizer, and insoluble in water.
- the water miscible oil droplets and active agent nanoparticles prepared using Route I or Route II can be filtered through either a 0.2 or 0.45 micron filter. Larger oil droplets and/or active agent particles can be created by simply increasing the water content, decreasing the oil-stabilizer-solvent content, or changing the shear in forming the oil droplets.
- the preferred ratio of oil:stabilizer:solvent is about 23: about 5: about 4, respectively, on a weight-to-weight basis.
- the preferred ratio of the oil comprising phase to water or buffer is about 2: about 1, respectively.
- the oil may be present at about 5% to about 50% (w/w); the solvent may be present at about 0.5% to about 10% (w/w); the stabilizer or surfactant may be present at about 0.5% to about 10% (w/w), the water may be present at about 20% to about 80 % (w/w), or any combination thereof.
- a first composition comprises: (1) at least one oil; (2) at least one solvent; (3) at least one surfactant or surface stabilizer; and (4) water.
- This composition exhibits broad spectrum antimicrobial activity and, therefore, the composition can be used as a general purpose disinfectant.
- Other types of compositions according to the invention comprise at least one active agent.
- a second composition can comprise: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer; (2) water or a buffer; (3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil and optionally at least one solvent; and optionally (4) microparticulate active agent.
- the microparticulate active agent can be the same as or different from the nanoparticulate active agent.
- the particulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof.
- a third composition comprises: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer; (2) water or buffer; and (3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil, optionally at least one solvent, and solubilized active agent.
- the composition may additionally comprise microparticulate active agent.
- the solubilized active agent can be present in the water or buffer, oil, solvent, or a combination thereof.
- nanoparticulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof.
- Such a composition is made utilizing Route II.
- the solubilized active agent can be precipitated out from the emulsion droplets.
- the precipitated active agent preferably has an effective average particle size of less than about 3 microns.
- the tri-phasic compositions of the invention are beneficial for several reasons. First, formulations resulting from the Route II method comprise both solid and solubilized forms of the same active agent. This enables a resultant pharmaceutical formulation to provide both immediate release and controlled release of the component active agent, providing for fast onset of activity combined with prolonged activity of the active agent.
- the solid active agent nanoparticles when formulated for topical application to the skin, in a cream or lotion for example, may provide an immediate local therapeutic effect at the skin surface, while the solubilized active agent within the emulsion base crosses the skin/cell barrier allowing the active agent to enter the body's system. That is, the solubilized active agent crosses the skin rapidly and penetrates into deeper layers, whereas the solid part does not permeate into deeper skin layers, but acts as local depot and as a reservoir for supplying drug into deeper layers.
- a formulation comprising both active agent nanoparticles and solubilized active agent can provide local and systemic therapeutic effects, which are particularly beneficial for transdermal dosage forms.
- the different components of the two types of compositions described above can be separated and, if desired, used independently.
- This invention permits many different types of active agents to be formulated into emulsion-based formulations.
- active agents include, but are not limited to, acyclovir, cyclosporine, estradiol, fenofibrate, ceterizine, nicotine, naltrexone, and alendronic acid.
- the solid active agent nanoparticles can be separated from the aqueous suspension media and/or the emulsion globules, for instance, by filtration or centrifugation. This provides a convenient method of obtaining nanoparticles of a poorly water-soluble or water- insoluble active agent. Furthermore, when a surface stabilizer is included in the particle size reduction process, it prevents the active agent nanoparticles from aggregating and, therefore, the active agent nanoparticles are stabilized at a nanoparticulate size. If desired, the active agent nanoparticles can then be formulated into any suitable dosage form. Active agent nanoparticles can be made using food grade, USP or NF grade materials suitable for human use applications.
- Exemplary dosage forms include, but are not limited to, liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups.
- the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof.
- compositions of the invention may be formulated for delivery via any suitable method, such as for parenteral injection (i.e., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, otic, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- parenteral injection i.e., intravenous, intramuscular, or subcutaneous
- oral administration in solid, liquid, or aerosol form vaginal, nasal, rectal, ocular, otic, local (powders, ointments or drops)
- buccal intracisternal
- intraperitoneal or topical administration, and the like.
- the active agent nanoparticles have an effective average particle size of less than about 3 microns, the particles typically are more readily able to move across absorption barriers, such as skin, as compared to microcrystalline active agent. Similarly, the small active agent particle size enables passage through blood/tissue and blood/tumor barriers of various organs.
- Emulsion Globules Comprising Active Agent Nanoparticles and/or Solubilized Active Agent
- the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can also be isolated, if desired, from the surrounding aqueous or buffer phase and used in therapeutic dosage forms.
- the emulsion globules can be made using food grade, USP or NF grade materials suitable for human use applications. Nanoparticulate oil globules comprising solubilized active agent, and methods of making the same, are described in U.S. Patent No. 5,629,021 ("the '021 patent”), which is incorporated herein by reference.
- the emulsion globules of the invention typically comprise: (1) at least one oil; (2) at least one solvent; (3) at least one surface stabilizer or surfactant; and optionally (4) solubilized active agent, particulate active agent, or a combination thereof.
- Emulsion globules comprising solubilized active agent, particulate active agent, or a combination thereof can be isolated, if desired, for example, by filtration.
- Emulsion globules comprising solubilized active agent are particularly suitable vehicles for transporting active agent across the skin barrier and into the blood. Hence, globules comprising solubilized active agent offer a systemic way to administer active agent to an individual.
- the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof have diameters of about 10 to about 1000 nm, and comprise a significant quantity of active agent, with a mean a diameter of less than about 1 micron preferred, and with the smallest globules filterable through a 0.2 micron filter, such as is typically used for microbiological purification.
- the range of active agent concentration in the globules can be from about 1% to about 50%.
- the emulsion globules can be stored at between about 20 to about 40 0 C.
- At least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the globules in the preparation have diameters of less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm.
- the size and integrity of such globules can be modified.
- the stability of globules comprising dissolved active agent can be altered to enable the release of active agent, either as a solution or precipitate.
- This is a microreservoir-dissolution-controlled system, where the drug solids acts as depot and, as the solubilized fraction is depleted, more drug is drawn into solution form the particulate depot.
- the emulsion globules comprising solubilized active agent enable controlled active agent release over time.
- the small size of the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof and their compatibility with tissue render them applicable to numerous uses.
- the emulsion globules are useful as topical drug delivery vehicles as they enable rapid dermal penetration.
- the globules are also exceptionally versatile in that the active agent utilized can be any active agent that is suspendable or dissolvable in any of the water or buffer, oil, or solvent. These properties allow this system to be used with active agents that are difficult to formulate for use in other delivery systems.
- the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can be diluted with aqueous solutions without stability loss. This enables the use of high active agent concentration, i.e. up to about 30%, products which can be diluted for use as necessary.
- the concentration of active agent depends on the solubility of the actual drug and the amount of solvent used to dissolve it.
- the emulsion globules comprise as an active agent estradiol, acyclovir, or testosterone and are formulated into a dosage form for transdermal delivery.
- any suitable active agent may be employed in the compositions and methods of the invention.
- the active agent For an active agent to be utilized in the Route I method, the active agent must be poorly soluble, or insoluble, in all phases of the milling ⁇ i.e., homogenization or vigorously stirring) system, including water and the solvent and oil to be used in the method.
- the active agent For an active agent to be utilized in Route II, the active agent must be poorly water soluble, or water insoluble, but soluble in at least one phase of the emulsion base, such as the oil or solvent and stabilizer or stabilizer solution.
- the active agent has a solubility in water of less than about than about 20 mg/mL, less than about 10 mg/mL, less than about 1 mg/mL, less than about 0.1 mg/mL, less than about 0.01 mg/mL, or less than about 0.001 mg/mL at ambient temperature and pressure and at about pH 7.
- the active agent to be used in the methods of the invention, and present in the compositions of the invention can be amorphous, semi-amorphous, crystalline, semi- crystalline, or a mixture thereof.
- active agent particle size is determined on the basis of the weight average particle size as measured by conventional techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, laser diffraction, or disk centrifugation.
- nanoparticulate active agent refers to active agent having an effective average particle size of less than about 3 microns
- microcrystalline active agent refers to active agent having an effective average particle size of greater than about 3 microns.
- an "effective average particle size" for an active agent is the size below which about 50% of the active agent particles fall. Thus, if the effective average particle size is less than about 3 microns, at least 50% of the active agent particles in the composition have a size of less than about 3 microns.
- the effective average particle size of the active agent particles in the compositions of the invention can be less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 300
- At least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% of the active agent particles have a size less than the effective average, i.e., less than about 3 microns, less than about 2900 nm, less than about 2800 nm, etc.
- any suitable active agent may be used in the methods and compositions of the invention.
- suitable active agent include, but are not limited to, therapeutic and diagnostic agents, pigments, paints, inks, dyes, photographic materials, cosmetic ingredients, etc.
- Amphiphile-type active agents may be incorporated into the present formulations.
- drugs or therapeutic compounds that can be ionized and are soluble in polar or non- polar solvents may be incorporated in the formulations of the present invention.
- Such compounds are soluble, therefore, both in oil and aqueous environments (amphiphiles). Examples of such compounds include nicotine and ceterizine.
- Hydrophilic active agents also may be incorporated into a formulation of the present invention. Such compounds include, but are not limited to naltrexone hydrochloride, alendronic acid, and ceterizine dihydrochloride.
- the active agent may be a hormone, such as testosterone, progesterone, and estrogen.
- Other hormones include: (1) Amine-derived hormones, such as catecholamines, adrenaline (or epinephrine), dopamine, noradrenaline (or norepinephrine), tryptophan derivatives, melatonin (N-acetyl-5-methoxytryptamine), serotonin (5-HT), tyrosine derivatives, thyroxine (T4), triiodothyronine (T3); (2) peptide hormones, such as antimullerian hormone (AMH, also mullerian inhibiting factor or hormone), adiponectin (also Acrp30), adrenocorticotropic hormone (ACTH, also corticotropin), angiotensinogen and angiotensin, antidiuretic hormone (ADH, also vasopressin, arginine vasopressin, AVP), atrial-natriure
- the active agent is estradiol, fenofibrate, acyclovir, alendronic acid, or testosterone.
- active agents include, but are not limited to, insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein, betaserori, erythropoietin, alpha interferon, beta interferon, gamma interferon, somatropin, somatotropin, somastostatin, insulin-like growth factor, luteinizing hormone releasing hormone, factor VIII, interleukins, interleukin analogues, hematological agents, anticoagulants, hematopoietic agents, hemostatics, thrombolytic agents, endocrine agents, antidiabetic agents, antithyroid agents, beta-adrenoceptor blocking agents, growth hormones, growth hormone releasing hormone, sex hormones, thyroid agents, parathyroid
- the active agent may be useful in the treatment of wound-healing.
- any suitable oil can be used.
- oils that can be used include, for example, vegetable oils, nut oils, fish oils, lard oil, mineral oils, squalane, tricaprylin, and mixtures thereof.
- oils that may be used include, but are not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), wheat germ oil, and mixtures thereof.
- compositions of the invention also comprise at leasfone surface stabilizer or surfactant.
- the surface stabilizer used in the methods and compositions of the invention associates with, or adsorbs to, the surface of the nanoparticulate active agent, but does not covalently bind to the active agent.
- the surface stabilizer is preferably soluble in water.
- One or more surface stabilizers may be used in the compositions and methods of the invention. As used herein, the terms “stabilizer”, “surface stabilizer”, and “surfactant” are used interchangeably.
- any suitable nonionic or ionic surfactant may be utilized in the compositions of the invention, including anionic, cationic, and zwitterionic surfactants.
- exemplary stabilizers or surfactants that may be used in the compositions of the invention lacking an active agent, and in active agent comprising compositions of the invention, include but are not limited to, non- phospholipid surfactants, such as the Tween ® (polyoxyethylene derivatives of sorbitan fatty acid esters) family of surfactants (i.e., Tween ® 20, Tween ® 60, and Tween ® 80), nonphenol polyethylene glycol ethers, sorbitan esters (such as Span ® and Arlacel ® ), glycerol esters (such as glycerin monostearate), polyethylene glycol esters (such as polyethylene glycol stearate), block polymers (such as Pluronics ® ), acrylic polymers (such as Pemulen ® ), ethoxy
- Any suitable solvent can be used in the methods and compositions of the invention.
- Exemplary solvents include, but are not limited, to isopropyl myristate, triacetin, N-methyl pyrrolidinone, long-chain alcohols, polyethylene glycols, propylene glycol, diethyleneglycol monoethyl ether, and long- and short-chain alcohols, such as ethanol.
- Other short chain alcohols and/or amides may be used, as well as aliphatic and aromatic alcohols, such as benzyl alchohol.
- Mixtures of solvents can also be used in the compositions and methods of the invention.
- the aqueous solution is preferably a physiologically compatible solution such as water or phosphate buffered saline.
- Volatile oils such as volatile flavor oils
- Exemplary volatile oils or fragrances that can be utilized in the invention include, but are not limited to, balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, origanum oil, and peppermint oil.
- a coloring agent such as a food coloring agent can also be used.
- Exemplary food colors that can be utilized in the compositions of the invention include, but are not limited to, green, yellow, red, and blue. The food colors utilized are food grade materials (McCormick), although materials from other sources can be substituted.
- a flavoring extract can be used in the methods and compositions of the invention.
- exemplary flavored extracts include, but are not limited to, pure anise extract (73% alcohol), imitation banana extract (40% ethanol), imitation cherry extract (24% ethanol), chocolate extract (23% ethanol), pure lemon extract (84% ethanol), pure orange extract (80% ethanol), pure peppermint extract (89% ethanol), imitation pineapple extract (42% ethanol), imitation rum extract (35% ethanol), imitation strawberry extract (30% ethanol). and pure or imitation vanilla extract (35% ethanol).
- the extracts utilized are food grade materials (McCormick), although materials from other sources can be substituted.
- compositions of the invention are useful as a broad spectrum antimicrobial agent. They can be used for topical or surface disinfection, for example, of biological and non- biological surfaces.
- the compositions can be used to disinfect surfaces likely to be exposed to microbes, such as cooking surfaces, eating surfaces, any surface in a hospital, areas exposed to young children, etc.
- Biological surfaces include skin, hair, mucous membranes, wound surfaces, insect bites, etc.
- compositions can also be used as delivery vehicles for an active agent, such as a drug or cosmetic.
- the compositions avoid the requirement of adding a antimicrobial agent to retard microbial growth.
- the compositions of the invention can be administered to a subject via any conventional means.
- the compositions can be useful in the formulation of active agents intended to treat wounds and would surfaces. Some of these active agents are not compatible with typical antimicrobial agents. Therefore, a vehicle that is inherently antimicrobial may be an ideal delivery system.
- compositions of the invention can be formulated into any suitable dosage form, such as liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups.
- the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof.
- the compositions of the invention may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
- Liquid dosage forms include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsif ⁇ ers.
- exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3- butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- “Therapeutically effective amount” as used herein with respect to an active agent dosage shall mean that dosage that provides the specific pharmacological response for which the active agent is administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount,” administered to a particular subject in a particular instance may not be effective for 100% of patients treated for a specific disease, and will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount” by those skilled in the art.
- an active agent can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form.
- Actual dosage levels of an active agent in the compositions of the invention may be varied to obtain an amount of the active agent that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered active agent, the desired duration of treatment, and other factors.
- Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose.
- the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
- Ethyl alcohol, soybean oil, and Polysorbate 80 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 1.
- the composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi.
- the mixture was run through the homogenizer for 2 passes.
- water can be added to the ethyl alcohol, oil, and Polysorbate 80 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
- the resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
- Estradiol is chemically described as estra-l,3,5(10)-triene-3,17beta -diol.
- the molecular formula of estradiol is C J gH 24 O 2 and the structural formula is:
- estradiol The molecular weight of estradiol is 272.39.
- estradiol products include oral pills (Estinyl ® , Estrace ® , Gynodiol ® , Ovcon 35 ® ), transdermal patches (Climara ® , Vivelle ® , Estraderm ® ), a vaginal ring (Estring ® ), and a topical emulsion (Estrasorb ® ).
- the drug is used in hormone replacement therapy, to treat moderate to severe symptoms of hot flashes and night sweats associated with menopause and to prevent pregnancy.
- Estradiol was dissolved in ethanol.
- the oil and Polysorbate 80 were added to the estradiol solution, water was added to the estradiol/ethyl alcohol/oil/Polysorbate 80 mixture, and the resulting composition was mixed well using a paddle stirrer.
- the quantities of each component are shown below in Table 2A.
- the composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi.
- the mixture was run through the homogenizer for 2 passes.
- the particle size of the composition is detailed in Table 2B below and is further represented in Figure 5.
- estradiol can be dissolved in ethyl alcohol, the oil and water can be added to the estradiol solution, and water can be added to the resulting composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
- the particle size of the composition according to the Silverson method is detailed in Table 2C below and is further represented in Figure 6.
- composition can be used directly as an estradiol topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
- Testosterone USP is a white to practically white crystalline powder chemically described as 17-beta hydroxyandrost-4-en-3-one.
- Testosterone has the chemical formula Ci 9 H 28 O 2 and a molecular weight of 288.42.
- Testosterone is commercially available, for example, in a injectable dosage forms, transdermal gel (AndroGel ® , Testim ® ), transdermal delivery device (Androderm ® , Testoderm ® ), and a buccal drug delivery system (Striant ® ). Testosterone is used, for example, in hormone replacement therapy.
- Testosterone was dissolved in ethyl alcohol. Oil and Polysorbate 80 were added to the testosterone solution, and water was added to the resulting composition. The resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 3A.
- the testosterone/ethyl alcohol/oil/Polysorbate 80/water composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
- the particle size of the composition is detailed in Table 3B below and is further represented in Figure 7.
- the testosterone can be dissolved in ethyl alcohol, and oil and the Polysorbate 80 can be added to the testosterone solution.
- Water can be added to the testosterone/ethyl alcohol/oil/Polysorbate 80 composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
- the resulting composition can be used directly as a testosterone topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
- Example 1 The purpose of this example was to determine the effect of concentration of excipients on the antimicrobial properties of the formulation.
- the composition of Example 1 was diluted with water by 10-fold and tested for antimicrobial effectiveness.
- composition did not meet the criteria set forth when tested according to USP Antimicrobial Effectiveness Testing standards.
- the resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti- yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
- Example 1 The purpose of this example was as yet another example to determine the effect of concentration of excipients on the antimicrobial properties of the formulation.
- the composition of Example 1 was diluted with water by 50-fold and tested for antimicrobial properties.
- composition did not meet the criteria set forth when tested according to USP Antimicrobial Effectiveness Testing standards.
- the resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti- yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
- the composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi.
- the mixture was run through the homogenizer for 2 passes.
- water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
- composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
- the composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi.
- the mixture was run through the homogenizer for 2 passes.
- water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
- composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
- Example 8
- the purpose of this example was to describe preparation of a nanostructured composition that included propofol, a model active pharmaceutical ingredient, and that did not meet the USP Antimicrobial Effectiveness Testing standards.
- the composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi.
- the mixture was run through the homogenizer for 2 passes.
- Example 1 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 1.
- Antimicrobial testing was conducted according to USP 25, ⁇ 51>, pp. 1869-1871.
- a quantity of the composition prepared as described in Example 1 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida Albicans (yeast), Escherichia coli (bacteria), Pseudomonas aeruginosa (bacteria), Staphylococcus aureus (bacteria), Aspergillus fumigatus (fungus), and Aspergillus flavus (fungus).
- compositions of the invention as antibacterial, antifungal, and anti-yeast agents.
- A. niger all organisms were eradicated after 7 days, and for A. niger, the growth of the organism was drastically diminished, with only 70 cfu/g measured on Day 28.
- the results demonstrate that the composition meets the USP 25 requirements for Antimicrobial Effectiveness Test.
- the purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 2, to determine if the addition of an active agent such as estradiol affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention.
- This example also evaluates the effect on antimicrobial activity of varying the quantity of alcohol present in the compositions of the invention. Antimicrobial testing was conducted according to USP 25, ⁇ 51>, pp. 1869-1871.
- a quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia coli (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
- the purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 3, to determine if the addition of an active agent such as testosterone affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention.
- Antimicrobial testing was conducted according to USP 25, ⁇ 51>, pp. 1869-1871.
- a quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia coli (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007240983A AU2007240983A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
EP07754559A EP2010149A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
JP2009504226A JP2009533341A (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, antifungal, antiyeast, and / or antiviral properties |
CA002648360A CA2648360A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78991706P | 2006-04-07 | 2006-04-07 | |
US60/789,917 | 2006-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007123790A1 true WO2007123790A1 (en) | 2007-11-01 |
Family
ID=38436994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/008054 WO2007123790A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2010149A1 (en) |
JP (1) | JP2009533341A (en) |
CN (1) | CN101466355A (en) |
AU (1) | AU2007240983A1 (en) |
CA (1) | CA2648360A1 (en) |
WO (1) | WO2007123790A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039864A1 (en) * | 2006-09-26 | 2008-04-03 | Novavax, Inc. | Emulsion formulations for transdermal delivery of poorly water soluble active agents |
WO2008051186A2 (en) | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
WO2009087474A2 (en) * | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
EP2448416A1 (en) * | 2009-06-30 | 2012-05-09 | The Trustees of Columbia University in the City of New York | Antimicrobial/preservative compositions comprising botanicals |
US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2014114851A1 (en) * | 2013-01-25 | 2014-07-31 | Kemira Oyj | Biocide composition and method for treating water |
US8932624B2 (en) | 2007-06-20 | 2015-01-13 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9497975B2 (en) | 2011-12-06 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Broad spectrum natural preservative composition |
US9511040B2 (en) | 2007-06-20 | 2016-12-06 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
WO2017002117A1 (en) * | 2015-07-01 | 2017-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Delivery systems for propofol |
US9687429B2 (en) | 2007-06-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing low concentrations of botanicals |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US9968101B2 (en) | 2011-11-03 | 2018-05-15 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
EP3332787A4 (en) * | 2015-09-30 | 2018-08-01 | Fujifilm Corporation | Transdermally absorbable composition |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
EP3351238A4 (en) * | 2015-09-17 | 2019-07-10 | Alaya (Shanghai) Bioscience Co., Ltd | Highly stable non-vesicular nanoparticles and application thereof in treating microbial infection |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806144B2 (en) | 2011-11-03 | 2020-10-20 | The Trustees Of Columbia University In The City Of New York | Composition with sustained antimicrobial activity |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2997304B1 (en) * | 2012-10-26 | 2017-07-07 | Isp Investments Inc | USE OF FLAX EXTRACT AS AN ACTIVATOR ACTIVE AGENT OF THE SYNTHESIS OF ANTIMICROBIAL PEPTIDES |
CN105241793B (en) * | 2015-09-07 | 2016-10-26 | 国家纳米科学中心 | A kind of assay method of carrier micelle form particle diameter |
CN113728865B (en) * | 2021-09-24 | 2022-12-13 | 广西壮族自治区亚热带作物研究所(广西亚热带农产品加工研究所) | Comprehensive management method for promoting flower and protecting fruit of macadimia nuts |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023409A1 (en) * | 1995-01-31 | 1996-08-08 | Novavax, Inc. | Micellar nanoparticles |
US20040043041A1 (en) * | 1999-04-28 | 2004-03-04 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
WO2005027872A2 (en) * | 2003-06-04 | 2005-03-31 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635676B2 (en) * | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
-
2007
- 2007-04-03 EP EP07754559A patent/EP2010149A1/en not_active Withdrawn
- 2007-04-03 AU AU2007240983A patent/AU2007240983A1/en not_active Abandoned
- 2007-04-03 CN CNA2007800213152A patent/CN101466355A/en active Pending
- 2007-04-03 JP JP2009504226A patent/JP2009533341A/en active Pending
- 2007-04-03 CA CA002648360A patent/CA2648360A1/en not_active Abandoned
- 2007-04-03 WO PCT/US2007/008054 patent/WO2007123790A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023409A1 (en) * | 1995-01-31 | 1996-08-08 | Novavax, Inc. | Micellar nanoparticles |
US20040043041A1 (en) * | 1999-04-28 | 2004-03-04 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
WO2005027872A2 (en) * | 2003-06-04 | 2005-03-31 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
ANDRZEJ MYC ET AL: "The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi", MYCOPATHOLOGIA, KLUWER ACADEMIC PUBLISHERS, DO, vol. 155, no. 4, 1 May 2003 (2003-05-01), pages 195 - 201, XP019259708, ISSN: 1573-0832 * |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008051186A2 (en) | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
WO2008051186A3 (en) * | 2005-08-09 | 2008-07-03 | Nanobio Corp | Nanoemulsion containing compositions having ant i -inflammatory activity |
WO2008039864A1 (en) * | 2006-09-26 | 2008-04-03 | Novavax, Inc. | Emulsion formulations for transdermal delivery of poorly water soluble active agents |
US8932624B2 (en) | 2007-06-20 | 2015-01-13 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US10542760B2 (en) | 2007-06-20 | 2020-01-28 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US9687429B2 (en) | 2007-06-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing low concentrations of botanicals |
US9511040B2 (en) | 2007-06-20 | 2016-12-06 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
WO2009087474A3 (en) * | 2008-01-08 | 2009-09-03 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
WO2009087474A2 (en) * | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
EP2448416A1 (en) * | 2009-06-30 | 2012-05-09 | The Trustees of Columbia University in the City of New York | Antimicrobial/preservative compositions comprising botanicals |
JP2012532141A (en) * | 2009-06-30 | 2012-12-13 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Antimicrobial / preservative composition containing plant components |
EP2448416A4 (en) * | 2009-06-30 | 2013-03-20 | Univ Columbia | Antimicrobial/preservative compositions comprising botanicals |
US10806144B2 (en) | 2011-11-03 | 2020-10-20 | The Trustees Of Columbia University In The City Of New York | Composition with sustained antimicrobial activity |
US9968101B2 (en) | 2011-11-03 | 2018-05-15 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
US8846648B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US8846649B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9497975B2 (en) | 2011-12-06 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Broad spectrum natural preservative composition |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9012434B2 (en) | 2012-06-18 | 2015-04-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9723833B2 (en) | 2013-01-25 | 2017-08-08 | Kemira Oyj | Biocide composition and method for treating water |
CN104936448A (en) * | 2013-01-25 | 2015-09-23 | 凯米罗总公司 | Biocide composition and method for treating water |
WO2014114851A1 (en) * | 2013-01-25 | 2014-07-31 | Kemira Oyj | Biocide composition and method for treating water |
RU2664302C2 (en) * | 2013-01-25 | 2018-08-16 | Кемира Ойй | Biocide composition and method for treating water |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2017002117A1 (en) * | 2015-07-01 | 2017-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Delivery systems for propofol |
US10568834B2 (en) | 2015-07-01 | 2020-02-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Delivery systems for propofol |
RU2709812C2 (en) * | 2015-07-01 | 2019-12-23 | Йиссум Ресерч Девелопмент Компани Оф Де Хебрю Юниверсити Оф Джерусалем Лтд | Propofol delivery systems |
US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US11266604B2 (en) | 2015-09-17 | 2022-03-08 | Alaya (Shanghai) Bioscience Co., Ltd. | Highly stable non-vesicular nanoparticles and application thereof in treating microbial infection |
AU2016321503B2 (en) * | 2015-09-17 | 2022-04-14 | Alaya (Shanghai) Bioscience Co., Ltd | Highly stable non-vesicular nanoparticles and application thereof in treating microbial infection |
RU2733320C2 (en) * | 2015-09-17 | 2020-10-01 | Алая (Шанхай) Биосайенс Ко., Лтд | Highly stable non-vesicular nanoparticles and use thereof in treating a microbial infection |
EP3351238A4 (en) * | 2015-09-17 | 2019-07-10 | Alaya (Shanghai) Bioscience Co., Ltd | Highly stable non-vesicular nanoparticles and application thereof in treating microbial infection |
EP3332787A4 (en) * | 2015-09-30 | 2018-08-01 | Fujifilm Corporation | Transdermally absorbable composition |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
EP2010149A1 (en) | 2009-01-07 |
CN101466355A (en) | 2009-06-24 |
JP2009533341A (en) | 2009-09-17 |
AU2007240983A1 (en) | 2007-11-01 |
CA2648360A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007123790A1 (en) | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties | |
Bajerski et al. | The use of Brazilian vegetable oils in nanoemulsions: an update on preparation and biological applications | |
US20070264349A1 (en) | Nano-structured compositions and methods of making and using the same | |
US6559189B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
US6635676B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
Pavoni et al. | Microemulsions: An effective encapsulation tool to enhance the antimicrobial activity of selected EOs | |
US8232320B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
US20100226983A1 (en) | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | |
US20110070306A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
Garcia et al. | Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils | |
AU2002350587A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
CN106727324B (en) | Nano silver liposome and its preparation method and application | |
CN101484138A (en) | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same | |
Gondim et al. | Plant extracts loaded in nanostructured drug delivery systems for treating parasitic and antimicrobial diseases | |
EP2633862B1 (en) | Compositions based on propolis nanocapsules which can be used as carriers for substances of interest, methods for producing same and use thereof | |
US20240082118A1 (en) | Topical compositions and methods of preparing the same | |
Manzoor et al. | Nanosizing of Lavender, Basil, and Clove Essential Oils into Microemulsions for Enhanced Antioxidant Potential and Antibacterial and Antibiofilm Activities | |
WO2005030172A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
Elmowafy et al. | Delivery Systems of Plant-Derived Antimicrobials | |
US11364199B1 (en) | Essential oil nanoemulsion and methods of use thereof | |
Singh et al. | Application of Nanoemulsion in Tuberculosis Treatment | |
Kaur et al. | Nanoemulsions: Status in Antimicrobial Therapy | |
WO2023250135A1 (en) | Nanoemulsion composite mixture of essential oils, biodegradable polymers and co-surfactants for antimicrobial activities | |
Cristiano et al. | 7 Technological Aspects | |
Pengon et al. | Nanoemulsions containing volatile oils as novel antimicrobial for oral health care products. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780021315.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07754559 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2648360 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009504226 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8437/DELNP/2008 Country of ref document: IN Ref document number: 2007240983 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007754559 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007240983 Country of ref document: AU Date of ref document: 20070403 Kind code of ref document: A |